Brief: Palvella Therapeutics Granted FDA Fast Track Designation For Qtorin™ 3.9% Rapamycin Anhydrous Gel For The Treatment Of Angiokeratomas
16/12/2025 12:31
Dec 16 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF ANGIOKERATOMAS PALVELLA THERAPEUTICS INC - PLANS PHASE 2 TRIAL FOR QTORIN RAPAMYCIN IN H2 2026 Source text: ID:nGNX724bV Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs